Apomorphine or ropinirole? New data sharpen the emetic choice

Apomorphine remains the faster, more familiar emetic for many emergency and toxicology cases in dogs, but ropinirole ophthalmic solution has carved out a meaningful role as the first FDA-approved drug specifically labeled to induce vomiting in dogs. Clevor (ropinirole ophthalmic solution) was approved by the FDA in June 2020 for in-clinic use by veterinary personnel, with field data showing 95% of treated dogs vomited within 30 minutes and 86% responded after the first dose. More recent comparative studies have complicated the picture: one 2023 clinical trial found ropinirole was less effective than apomorphine at inducing vomiting, though both were similarly effective at removing ingested material, while a 2025 emergency-setting study conducted at 2 specialty referral hospitals in 132 client-owned dogs reported lower first-dose success, longer time to emesis, and more minor adverse events with ropinirole than with IV apomorphine. That 2025 trial also reflects how these drugs are being used in real ER presentations, including suspected or confirmed ingestion of toxic foods, plants, medications, rodenticides, and foreign material. (fda.gov)

Why it matters: For veterinary teams, this is increasingly a workflow and case-selection question, not just a pharmacology debate. Apomorphine is still widely viewed as the stronger option when speed matters, especially in urgent decontamination, but it is used extra-label in the U.S. and may require compounding and hazardous-drug handling precautions. Ropinirole offers an FDA-approved, ophthalmic alternative that may be easier to administer in some patients and settings, though it comes with labeled age and weight restrictions and may not match IV apomorphine’s speed in the ER. The 2025 emergency trial excluded dogs younger than 4.5 months, under 1.8 kg, with ocular disease, CNS or hepatic disease, prior antiemetic use, or ingestions where emesis was contraindicated, underscoring how much patient selection still drives the choice. Guidance from Illinois notes ropinirole may be the comparatively safer option for staff and some patients when labeled criteria are met and there are no ophthalmic concerns. (vetmed.illinois.edu)

What to watch: Expect more protocol-level decisions in ER and general practice around which dogs are best suited to ropinirole versus apomorphine as newer head-to-head data shape toxicology and decontamination workflows. Separately, clinics may also be watching antiemetic inventory changes: Dechra says Emeprev, an FDA-approved bioequivalent maropitant injectable for dogs and cats, is expected through major distributors in early 2026, with no refrigeration required and less injection pain in dogs than the pioneer drug in lab studies. (pubmed.ncbi.nlm.nih.gov)